Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond
暂无分享,去创建一个
[1] Frédéric Blanchard,et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK , 2006 .
[2] R. Steinman,et al. TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.
[3] Qiongqing Wang,et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. , 2009, Genes & development.
[4] T. Taniguchi,et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis , 2004, Nature.
[5] Shuying Yang,et al. RGS10-null mutation impairs osteoclast differentiation resulting from the loss of [Ca2+]i oscillation regulation. , 2007, Genes & development.
[6] J. Penninger,et al. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis , 2005, Nature Medicine.
[7] Allan Bradley,et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.
[8] D. Lo,et al. Jagged1 and Notch1 help edit M cell patterning in Peyer's patch follicle epithelium. , 2012, Developmental and comparative immunology.
[9] R. Faccio,et al. The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo , 2009, Proceedings of the National Academy of Sciences.
[10] Hao Wu,et al. Distinct molecular mechanism for initiating TRAF6 signalling , 2002, Nature.
[11] H. Hanafusa,et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. , 1999, Molecular cell.
[12] T. Miyata,et al. Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors , 1999, The Journal of experimental medicine.
[13] M. Walsh,et al. Biology of the TRANCE axis. , 2003, Cytokine & growth factor reviews.
[14] B. Aggarwal,et al. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. , 1999, The Journal of biological chemistry.
[15] S. Nishikawa,et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.
[16] M. Habal,et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism , 2001, Nature Genetics.
[17] J. Cheng,et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.
[18] N. Sakamoto,et al. RANK-RANKL Signaling Pathway Is Critically Involved in the Function of CD4+CD25+ Regulatory T Cells in Chronic Colitis1 , 2009, The Journal of Immunology.
[19] T. Kodama,et al. Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals , 2008, Cell.
[20] A. Kudo,et al. Self‐Assembled RANK Induces Osteoclastogenesis Ligand‐Independently , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] G D Roodman,et al. Cell biology of the osteoclast. , 1999, Experimental hematology.
[22] Yasuhiro Kobayashi,et al. Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. , 2011, Frontiers in bioscience.
[23] I. Holen,et al. Targeting RANKL in metastasis , 2014, BoneKEy reports.
[24] L. Bonewald,et al. MLO‐Y4 Osteocyte‐Like Cells Support Osteoclast Formation and Activation , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] E. Wagner,et al. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation , 2000, Nature Genetics.
[26] Kosaku Kurata,et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression , 2011, Nature Medicine.
[27] S. M. Sims,et al. Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.
[28] T. Taniguchi,et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. , 2000, Nature.
[29] F. Kronenberg,et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus , 2013, Nature Medicine.
[30] Zhijian J. Chen,et al. Ubiquitination in signaling to and activation of IKK , 2012, Immunological reviews.
[31] Hiroshi Takayanagi,et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis , 2013, Nature Medicine.
[32] John C. Lee,et al. Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.
[33] G. Rodan,et al. Pathogenesis of osteoporosis. , 2003, Endocrinology and metabolism clinics of North America.
[34] Wassim Raffoul,et al. Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast , 2013, Science Translational Medicine.
[35] M. Naramura,et al. A Positive Regulatory Role for Cbl Family Proteins in Tumor Necrosis Factor-related Activation-induced Cytokine (TRANCE) and CD40L-mediated Akt Activation* , 2001, The Journal of Biological Chemistry.
[36] R. Schüle,et al. FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. , 2005, The Journal of clinical investigation.
[37] J. Penninger,et al. Receptor activator of NF-κB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit , 2011, Proceedings of the National Academy of Sciences.
[38] A. Kudo,et al. TRAF2 Is Essential for TNF‐α‐Induced Osteoclastogenesis , 2004 .
[39] H. Blair,et al. Tumor Necrosis Factor Family Receptors Regulating Bone Turnover , 2007, Annals of the New York Academy of Sciences.
[40] P. Kostenuik,et al. Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab , 2012, Nature Reviews Drug Discovery.
[41] D. Lacey,et al. The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.
[42] S. Morony,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[43] H. Kiyono,et al. RANKL Is Necessary and Sufficient to Initiate Development of Antigen-Sampling M Cells in the Intestinal Epithelium1 , 2009, The Journal of Immunology.
[44] H. Takayanagi. New developments in osteoimmunology , 2012, Nature Reviews Rheumatology.
[45] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[46] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[47] Hiroshi Takayanagi,et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.
[48] B. Riggs,et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. , 1998, Biochemical and biophysical research communications.
[49] B. Olsen,et al. Increased Myeloid Cell Responses to M-CSF and RANKL Cause Bone Loss and Inflammation in SH3BP2 “Cherubism” Mice , 2007, Cell.
[50] E. Wagner,et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms , 2002, Journal of Cell Science.
[51] M. Widschwendter,et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer , 2010, Nature.
[52] T. Akiyama,et al. Regulations of Gene Expression in Medullary Thymic Epithelial Cells Required for Preventing the Onset of Autoimmune Diseases , 2013, Front. Immunol..
[53] W. Dougall,et al. A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function* , 2002, The Journal of Biological Chemistry.
[54] E. Schmidt,et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. , 2001, Cell.
[55] S. Yamasaki,et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. , 2000, Biochemical and biophysical research communications.
[56] B. Kwon,et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[57] A. Leonardi,et al. Requirement for NF-kappaB in osteoclast and B-cell development. , 1997, Genes & development.
[58] A. Kudo,et al. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[59] Y. Kadono,et al. Osteoimmunology: interplay between the immune system and bone metabolism. , 2006, Annual review of immunology.
[60] G. Mundy. Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.
[61] Hiroshi Takayanagi,et al. Mechanistic insight into osteoclast differentiation in osteoimmunology , 2005, Journal of Molecular Medicine.
[62] D. Branstetter,et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis , 2010, Nature.
[63] Mark S. Anderson,et al. Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance , 2014, The Journal of Experimental Medicine.
[64] R. Steinman,et al. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. , 1999, Journal of immunology.
[65] H. Kitaura,et al. Immunological Reaction in TNF-α-Mediated Osteoclast Formation and Bone Resorption In Vitro and In Vivo , 2013, Clinical & developmental immunology.
[66] W. Dougall,et al. RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.
[67] T. Martin,et al. Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction , 2022 .
[68] B. Aggarwal,et al. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. , 1998, The Journal of biological chemistry.
[69] S. Akira,et al. TRAF Family Member-associated NF-κB Activator (TANK) Is a Negative Regulator of Osteoclastogenesis and Bone Formation* , 2012, The Journal of Biological Chemistry.
[70] E. Wagner,et al. NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1* , 2007, Journal of Biological Chemistry.
[71] T. Suda,et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. , 2001, Blood.
[72] T. Takeya,et al. Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator* , 2002, The Journal of Biological Chemistry.
[73] H. Ryoo,et al. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross‐talking with RANK signaling , 2008, Journal of cellular physiology.
[74] Jinhu Xiong,et al. Matrix-embedded cells control osteoclast formation , 2011, Nature Medicine.
[75] T. Martin,et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.
[76] C. O’Brien,et al. Osteocyte RANKL: New insights into the control of bone remodeling , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[77] C. Mueller,et al. Emerging Functions of RANKL in Lymphoid Tissues , 2012, Front. Immun..
[78] L. Hofbauer,et al. Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.
[79] N A Mabbott,et al. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium , 2013, Mucosal Immunology.
[80] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[81] Y. Kadono,et al. Strength of TRAF6 signalling determines osteoclastogenesis , 2005, EMBO reports.
[82] L. Xing,et al. NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. , 2009, The Journal of clinical investigation.
[83] Natalie A. Roberts,et al. Rank Signaling Links the Development of Invariant γδ T Cell Progenitors and Aire+ Medullary Epithelium , 2012, Immunity.
[84] I. Williams,et al. Distinct developmental requirements for isolated lymphoid follicle formation in the small and large intestine: RANKL is essential only in the small intestine. , 2011, The American journal of pathology.
[85] M. Karin,et al. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2009, Nature.
[86] Shao-Cong Sun,et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. , 2008, The Journal of clinical investigation.
[87] D. Lacey,et al. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .
[88] K. Hirokawa,et al. Multimerization of the Receptor Activator of Nuclear Factor-κB Ligand (RANKL) Isoforms and Regulation of Osteoclastogenesis* , 2003, Journal of Biological Chemistry.
[89] David A. Cheresh,et al. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2007, Nature.
[90] Hyunsook Kim,et al. Tmem64 modulates calcium signaling during RANKL-mediated osteoclast differentiation. , 2013, Cell metabolism.
[91] T. Izumi. [Management of bone disease in multiple myeloma]. , 2012, Gan to kagaku ryoho. Cancer & chemotherapy.
[92] S. Mochizuki,et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.
[93] M. Kumegawa,et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. , 1998, Biochemical and biophysical research communications.
[94] W. de Lau,et al. Peyer's Patch M Cells Derived from Lgr5+ Stem Cells Require SpiB and Are Induced by RankL in Cultured “Miniguts” , 2012, Molecular and Cellular Biology.
[95] L. Xing,et al. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. , 2014, The Journal of clinical investigation.
[96] T. Kodama,et al. Osteoprotection by semaphorin 3A , 2012, Nature.
[97] N. Sakurai,et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. , 2002, Molecular and cellular biology.
[98] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[99] A. Mócsai,et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[100] I. Ishikawa,et al. LPS‐stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin , 2002, Clinical and experimental immunology.
[101] T. Nishihara,et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. , 2002, Endocrinology.
[102] H. Takayanagi,et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. , 2008, Immunity.
[103] Sakae Tanaka,et al. Severe osteopetrosis, defective interleukin‐1 signalling and lymph node organogenesis in TRAF6‐deficient mice , 1999, Genes to cells : devoted to molecular & cellular mechanisms.
[104] E. Wagner,et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.
[105] Sundeep Khosla,et al. The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[106] Steffen Jung,et al. Regulation of Peripheral Lymph Node Genesis by the Tumor Necrosis Factor Family Member Trance , 2000, The Journal of experimental medicine.
[107] G. Mundy. Osteoporosis and inflammation. , 2007, Nutrition reviews.
[108] Hiroshi Takayanagi,et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.
[109] R. Steinman,et al. The TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor* , 1998, The Journal of Biological Chemistry.
[110] T. Komori,et al. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). , 1998, Biochemical and biophysical research communications.
[111] C. O’Brien,et al. Receptor Activator of Nuclear Factor κB Ligand (RANKL) Protein Expression by B Lymphocytes Contributes to Ovariectomy-induced Bone Loss* , 2012, The Journal of Biological Chemistry.
[112] S. Ricard-Blum,et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. , 2006, Biochemical and biophysical research communications.
[113] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[114] Y. Kong,et al. Survival and Differentiation of Mammary Epithelial Cells in Mammary Gland Development Require Nuclear Retention of Id2 Due to RANK Signaling , 2011, Molecular and Cellular Biology.
[115] E. Schmidt,et al. IKKα Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland Development , 2001, Cell.
[116] J. Branco,et al. Rank/Rankl/opg: literature review. , 2011, Acta reumatologica portuguesa.
[117] A. Mizokami,et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.
[118] M. Whyte,et al. Expansile Skeletal Hyperphosphatasia Is Caused by a 15‐Base Pair Tandem Duplication in TNFRSF11A Encoding RANK and Is Allelic to Familial Expansile Osteolysis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[119] T. Kaisho,et al. The Ets Transcription Factor Spi-B Is Essential for the Differentiation of Intestinal Microfold (M) Cells , 2012, Nature Immunology.
[120] M. Heymann,et al. Osteoprotegerin: multiple partners for multiple functions. , 2013, Cytokine & growth factor reviews.
[121] D. Lacey,et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.
[122] R. Locksley,et al. The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.
[123] J. Caamaño,et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. , 1997, Nature medicine.
[124] R. Flavell,et al. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. , 2002, Immunity.
[125] J. Caamaño,et al. The thymic medulla is required for Foxp3+ regulatory but not conventional CD4+ thymocyte development , 2013, The Journal of experimental medicine.
[126] S. Morony,et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.
[127] J. Penninger,et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells , 2006, Nature Medicine.
[128] R. Wallace,et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.
[129] R. Steinman,et al. Trance, a Tumor Necrosis Factor Family Member, Enhances the Longevity and Adjuvant Properties of Dendritic Cells in Vivo , 2000, The Journal of experimental medicine.
[130] Ulrich Siebenlist,et al. Requirement for NF-κB in osteoclast and B-cell development , 1997 .
[131] W. Dougall,et al. The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily* , 1998, The Journal of Biological Chemistry.
[132] T. Yoneda,et al. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. , 1992, The Journal of clinical investigation.
[133] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[134] J. Penninger,et al. Receptor Activator of NF-κB Ligand Regulates the Proliferation of Mammary Epithelial Cells via Id2 , 2006, Molecular and Cellular Biology.
[135] D. Lacey,et al. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. , 1999, Bone.
[136] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[137] L. Hood,et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. , 1998, Journal of immunology.
[138] G. Bishop,et al. TRAF3 enforces the requirement for T cell cross-talk in thymic medullary epithelial development , 2013, Proceedings of the National Academy of Sciences.
[139] Kozo Nakamura,et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β , 2002, Nature.
[140] N. Nagata,et al. Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like Cells , 1998 .
[141] J. Penninger,et al. RANKL/RANK - from bone physiology to breast cancer. , 2014, Cytokine & growth factor reviews.
[142] B. Boyce. Advances in the Regulation of Osteoclasts and Osteoclast Functions , 2013, Journal of dental research.
[143] A. Mócsai,et al. The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase , 2004 .
[144] W. Zou,et al. DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. , 2008, Molecular cell.
[145] Masaru Ishii,et al. Dynamic visualization of RANKL and Th17-mediated osteoclast function. , 2013, The Journal of clinical investigation.